Pharma giant Roche nets PathAI to bolster AI-driven diagnostics
Swiss pharmaceutical company Roche agreed to acquire U.S.-based PathAI for $750 million to expand its AI-driven diagnostics capabilities, with potential milestone payments of up to $300 million. The deal, pending regulatory approval, aims to enhance digital pathology tools for cancer diagnosis and improve workflow efficiency through high-resolution imaging technology.
Swiss pharmaceutical giant Roche announced on Thursday it will acquire Boston-based PathAI, a specialist in AI and digital imaging solutions for diagnostics. The deal, valued at $750 million (637 million euros), includes an additional $300 million in possible milestone payments and is expected to close in the second half of 2024, pending regulatory approval. Roche has collaborated with PathAI since 2021, strengthening their partnership in 2024 to develop AI-powered algorithms for diagnostic purposes. The acquisition will bolster Roche’s position in digital pathology, enabling high-resolution tissue imaging and improving diagnosis accuracy, particularly for cancer detection. According to Roche, the integration of PathAI’s technology will transform diagnostic workflows by automating image analysis and enhancing precision. Urban Fritsche, an analyst at Zurich Kantonalbank, noted the acquisition is a smaller deal that won’t immediately impact sales but will provide a critical platform for future advancements. The move reflects Roche’s strategy to leverage AI in healthcare diagnostics, building on its existing partnerships and expanding its capabilities in digital health solutions. Roche shares rose approximately 0.6% to 324 francs in mid-morning trading on Thursday.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.